Related Experiment Video
Updated: Jan 20, 2026
Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
Published on: May 10, 2024
Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice
Yan Chen1, Ting Yang2, Jing Zhang3
1Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Research Unit of Respiratory Disease, Central South University; Clinical Medical Research Center for Pulmonary and Critical Care Medicine in Hunan Province; Diagnosis and Treatment Center of Respiratory Disease in Hunan Province, Changsha, Hunan 410011, China.
Background:
Type 2 inflammation is a key inflammatory endotype of chronic obstructive pulmonary disease (COPD). The precise identification and targeted intervention of treatable traits related to type 2 inflammation are crucial directions in the current management of COPD. Recently, a growing body of evidence-based medical data has accumulated regarding the clinical characteristics, biomarkers, therapeutic agents, and efficacy evaluation of type 2 inflammation in COPD, providing strong support for clinical diagnosis and treatment. This clinical practice recommendation systematically reviewed the evidence-based medical literature and integrated clinical experience to present expert opinions, aiming to standardize and improve the management of type 2 inflammation in COPD.
Methods:
This clinical practice recommendation followed Appraisal of Guidelines for Research and Evaluation II (AGREE II) and the Reporting Items for Practice Guidelines in HealThcare (RIGHT) statement to ensure the thoroughness and transparency. Clinical questions were primarily derived from surveys among experts in the field and thorough discussion at meetings. The evidence grading levels and recommendation grades adopted in the clinical practice recommendation follow the evidence grading levels and recommendation grades established by the Oxford Centre for Evidence-Based Medicine. The expert opinions were formulated through open discussion and expert voting. Expert opinions with an agreement rate of 80 % or higher among the experts are incorporated in the clinical practice recommendation.
Results:
Eight clinical questions concerning diagnosis and treatment were proposed after expert discussion. In addition, fifteen specific major points of expert opinions about type 2 inflammation in COPD, involving clinical features, biomarkers, correlation with clinical outcomes, inhaled corticosteroid (ICS) treatment, biologic treatment and treatment response, were determined.
Conclusions:
A set of comprehensive clinical practice recommendations focusing on the treatable trait of type 2 inflammation in COPD was established, which may provide potential guidance for the precision management of COPD.
Related Concept Videos
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
02:34Auricular Acupressure as an Adjuvant Treatment for Wheezing in Stable Chronic Obstructive Pulmonary Disease
08:17Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation